Zhejiang Aisheng Pharmaceutical Co. Ltd.

Main study objectives: In healthy subjects, in the postprandial state, using Drospirenone Ethinyl Estradiol Tablets (II) (trade name: Yousiyue, specification: 3 mg drospirenone and 0.02 mg ethinyl estradiol) produced by Bayer Weimar GmbH und Co.KG and licensed by Bayer Australia Ltd as the reference preparation, to study the absorption rate and extent of Drospirenone Ethinyl Estradiol Tablets (II) (test preparation, specification: 0.020 mg ethinyl estradiol and 3.000 mg drospirenone) developed by Zhejiang Aisheng Pharmaceutical Co., Ltd., and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary study objectives: Observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main study objectives: In healthy subjects, under fasting conditions, using Drospirenone Ethinyl Estradiol Tablets (II) (trade name: Usile, specification: 3 mg drospirenone and 0.02 mg ethinyl estradiol) produced by Bayer Australia Ltd and Bayer Weimar GmbH und Co.KG as the reference preparation, to study the absorption rate and extent of Drospirenone Ethinyl Estradiol Tablets (II) (test preparation, specification: 0.020 mg ethinyl estradiol and 3.000 mg drospirenone) developed by Zhejiang Aisheng Pharmaceutical Co., Ltd., and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary study objectives: Observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

To study the pharmacokinetics of a single oral dose of the test preparation Dydrogesterone Tablets and the reference preparation Dydrogesterone Tablets in healthy female subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. To study the safety of the test preparation Dydrogesterone Tablets and the reference preparation in healthy female subjects.